Robert Jr. Baltera Buys 10,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 10,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was acquired at an average price of $1.98 per share, for a total transaction of $19,800.00. Following the transaction, the director owned 366,904 shares of the company’s stock, valued at approximately $726,469.92. The trade was a 2.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 1st, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Stock Up 2.0%

Shares of PALI opened at $2.08 on Wednesday. The stock has a market cap of $361.05 million, a PE ratio of -2.06 and a beta of 1.50. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.86. The business has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $1.92.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, equities research analysts expect that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on PALI shares. Wolfe Research started coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Oppenheimer set a $7.00 target price on Palisade Bio in a research report on Tuesday, June 30th. Finally, LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.83.

Institutional Investors Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in PALI. Cetera Investment Advisers purchased a new position in shares of Palisade Bio in the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC purchased a new stake in Palisade Bio during the fourth quarter worth about $28,000. CTC Alternative Strategies Ltd. bought a new stake in Palisade Bio in the first quarter worth about $31,000. Finally, Atom Investors LP bought a new stake in Palisade Bio in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.